<p>Revelation Biosciences, Inc.（纳斯达克代码：REVB）（以下简称 “公司” 或 “Revelation”）是一家专注于重新平衡炎症的临床阶段生命科学公司，今天宣布，2026 年 1 月 8 日，Revelation 董事会薪酬委员会批准了一项诱导性授予，包括 90,000 个限制性股票单位（“RSUs”），涵盖 90,000 股公司普通股，授予一名新的非执行员工。该 RSUs 是在公司股东批准的股权激励计划之外授予的。根据纳斯达克上市规则 5635(c)(4)，该奖励作为员工接受 Revelation 工作的诱因。</p>
<p>这些 RSUs 将在两年内按季度均等归属，从员工的新入职日期后的第一个季度归属日期开始，前提是员工在归属日期之前继续为公司服务。</p>
<p><strong>关于 Revelation Biosciences, Inc.</strong></p>
<p>Revelation Biosciences, Inc.是一家临床阶段生命科学公司，专注于使用其专有配方 Gemini 重新平衡炎症。Revelation 有多个正在进行的项目来评估 Gemini，包括慢性肾病的治疗、术后感染的预防以及急性肾损伤的治疗。</p>
<p>有关 Revelation 的更多信息，请访问 www.RevBiosciences.com。</p>
<p><strong>公司联系方式</strong></p>
<p>Mike Porter</p>
<p><em>投资者关系</em></p>
<p>Porter LaVay &amp; Rose Inc.</p>
<p>电子邮件：mike@plrinvest.com</p>
<p>Chester Zygmont, III</p>
<p><em>首席财务官</em></p>
<p>Revelation Biosciences Inc.</p>
<p>电子邮件：czygmont@revbiosciences.com</p>
<p><strong>来源：</strong> Revelation Biosciences, Inc.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjQ1NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjQ1NA"/></p>

REVB

<p>Revelation Biosciences, Inc.（纳斯达克代码：REVB）于 2026 年 1 月 8 日宣布向一名新非执行员工授予 90,000 个限制性股票单位（RSUs）的激励补助，该补助已获得其薪酬委员会的批准。此项授予是在股东批准的股权激励计划之外进行的，符合纳斯达克上市规则 5635(c)(4)，将根据员工的持续服务在两年内按季度分期归属。Revelation 专注于通过其专有配方 Gemini 来重新平衡炎症，并正在进行针对各种医疗状况的项目</p>

<p>Revelation Biosciences, Inc. (NASDAQ:REVB) (the &#34;Company&#34; or &#34;Revelation&#34;), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced that on January 8, 2026, the Compensation Committee of Revelation's Board of Directors approved an inducement grant consisting of 90,000 restricted stock units (&#34;RSUs&#34;) covering 90,000 shares of the Company's common stock to a new non-executive employee. The RSUs were granted outside of the Company's stockholder-approved equity incentive plan. The award was granted as an inducement material to the employee's acceptance of employment with Revelation in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>Revelation Biosciences, Inc.（纳斯达克代码：REVB）（以下简称 “公司” 或 “Revelation”）是一家专注于重新平衡炎症的临床阶段生命科学公司，今天宣布，2026 年 1 月 8 日，Revelation 董事会薪酬委员会批准了一项诱导性授予，包括 90,000 个限制性股票单位（“RSUs”），涵盖 90,000 股公司普通股，授予一名新的非执行员工。该 RSUs 是在公司股东批准的股权激励计划之外授予的。根据纳斯达克上市规则 5635(c)(4)，该奖励作为员工接受 Revelation 工作的诱因。</p>
</div><p>The RSUs will vest over two years in equal quarterly installments, beginning on the first quarterly vesting date following the employee's new hire date, subject to the employee's continued service with the Company through the vesting dates.</p>
<div class="lb-trans"><p>这些 RSUs 将在两年内按季度均等归属，从员工的新入职日期后的第一个季度归属日期开始，前提是员工在归属日期之前继续为公司服务。</p>
</div><p><strong>About Revelation Biosciences, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Revelation Biosciences, Inc.</strong></p>
</div><p>Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.</p>
<div class="lb-trans"><p>Revelation Biosciences, Inc.是一家临床阶段生命科学公司，专注于使用其专有配方 Gemini 重新平衡炎症。Revelation 有多个正在进行的项目来评估 Gemini，包括慢性肾病的治疗、术后感染的预防以及急性肾损伤的治疗。</p>
</div><p>For more information on Revelation, please visit www.RevBiosciences.com.</p>
<div class="lb-trans"><p>有关 Revelation 的更多信息，请访问 www.RevBiosciences.com。</p>
</div><p><strong>Company Contact</strong></p>
<div class="lb-trans"><p><strong>公司联系方式</strong></p>
</div><p>Mike Porter</p>
<div class="lb-trans"><p>Mike Porter</p>
</div><p><em>Investor Relations</em></p>
<div class="lb-trans"><p><em>投资者关系</em></p>
</div><p>Porter LaVay &amp; Rose Inc.</p>
<div class="lb-trans"><p>Porter LaVay &amp; Rose Inc.</p>
</div><p>Email: mike@plrinvest.com</p>
<div class="lb-trans"><p>电子邮件：mike@plrinvest.com</p>
</div><p>Chester Zygmont, III</p>
<div class="lb-trans"><p>Chester Zygmont, III</p>
</div><p><em>Chief Financial Officer</em></p>
<div class="lb-trans"><p><em>首席财务官</em></p>
</div><p>Revelation Biosciences Inc.</p>
<div class="lb-trans"><p>Revelation Biosciences Inc.</p>
</div><p>Email: czygmont@revbiosciences.com</p>
<div class="lb-trans"><p>电子邮件：czygmont@revbiosciences.com</p>
</div><p><strong>SOURCE:</strong> Revelation Biosciences, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Revelation Biosciences, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjQ1NA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1126454"/></p>

Revelation Biosciences 根据纳斯达克上市规则 5635(c)(4) 报告授予诱导性股票 | REVB 股票新闻